Jeff Mirviss, executive vice president of Boston Scientific’s peripheral business, explains why the specialty’s name doesn’t really reflect the importance of arteries, veins and other “highways” that his business group is addressing. Mirviss explains where the peripheral business is headed, and  why Boston Scientific is uniquely positioned to address the business.

He also shares lessons learned over his 20-plus years at Boston Scientific including the challenges presented by the Guidant acquisition and the new spirit infused by CEO Michael Mahoney.

We also speak with Eric Kolodziej, corporate vice president and global head quality and regulatory affairs at Hologic, about how clinical trial management is changing. What role will real world evidence play going forward, and how will Hologic and others follow up on the record number of EUA’s issued over the past year by the FDA.


Chris Newmarker, executive editor of life sciences at Mass Device, delivers his Newmarker’s Newsmakers bringing news from Medtronic, Abbott, Zimmer Biomet and Shockwave. Pharma Editor Brian Buntz also sits in the virtual booth to talk about the new Pharma 50 report compiled by our editorial team.

Subscribe today on most major podcast applications

Getting to the heart of Boston Scientific’s peripheral business; How Hologic sees trials changing

Edward Lifesciences’ acquisition of Percutaneous Valve Technologies helped mark the birth of one of medtech’s great game-changers – the development of the transcatheter aortic valve replacement.

In this week’s episode, Stanton Rowe, the former CEO of PVT, will walk us through the early days of TAVR, including the enormous doubt the start-up faced as it developed the technology. He also explained how Edwards came to acquire the start-up, which had strong interest from Medtronic, Boston Scientific, and others.

Rowe, who is now CEO of the NXT Biomedical incubator, also offers some provocative thoughts on the origins of medtech innovation (and explains why he misses medical device conferences.)

Larry Wood, corporate vice president at Edwards Lifesciences, will explain why Edwards opted to pursue PVT rather than continue to develop its own TAVR technology.

He also explains why the clinical trial testing of the valve now known as Sapien was so difficult and how he rewrote the compensation packages for his TAVR sales team to help build confidence in the new technology.

Scan the QR code for more information about our upcoming DeviceTalks Tuesday discussion with Sagentia! 

You can subscribe to this podcast on most major podcast players including Amazon, Apple, Google, and Spotify.

The Complete History of the Sapien TAVR – from PVT’s Emerging Idea to Edwards Lifesciences' Success

In this episode of IntuitiveTalks, we take our first look at Intuitive’s Future Forward program, a three-piece initiative to better understand how the company fits best into an evolving healthcare landscale. Our guests are Julian Nikolchev, an experienced medical device entrepreneur and investor who now serves as SVP, Development and Strategy at the Intuitive. Nikolchev led the creation of Intuitive Ventures, a $100 million corporate venture capital program led by our second guest, Oliver Keown, MD, a physician turned investor who is leading the creation of an intriguing portfolio of digital and medical device companies that will help inform Intuitive’s future. You can see Intuitive’s full team and portfolio here. https://ventures.intuitive.com/

IntuitiveTalks – How a new venture group keeps Intuitive’s eyes focused forward on the future

In this episode, we’ll talk to two of the more innovative companies in the peripheral vascular space – Shockwave Medical and LimFlow – about how they’re helping to treat people who previously had few or zero options.

This episode is brought to you by Confluent Medical.

LimFlow CEO Dan Rose walked us through his decision to build his Medtech career in Europe. He also talked about LimFlow’s unique approach to using veins as a route to deliver blood to limbs rather than return blood to the heart.

Our second interview is with Doug Godshall, CEO and President of Shockwave Medical. Godshall admittedly came to medtech later in his career, but he’s taken on some of its most serious and intractable problems, first as CEO of HeartWare and now Shockwave Medical.

You can learn more about Shockwave here 

https://shockwavemedical.com/about/our-story/

and LimFlow here.

https://limflow.com/

We’ll also have Chris Newmarker delivering his Newmarker’s Newsmakers including news from Philips, Johnson & Johnson MedTech, Natus Medical, Amazon Web Services, and Dentsplay Sirona.

Subscribe to this podcast on all major podcast apps.


#5 https://www.massdevice.com/philips-has-another-round-of-serious-ventilator-recalls/

#4 https://www.massdevice.com/johnson-johnson-medtech-is-shopping-for-ma-deals/

#3 https://www.massdevice.com/archimed-group-to-acquire-natus-medical-for-1-2b/

#2 https://www.medicaldesignandoutsourcing.com/amazon-web-services-aws-cloud-chief-medical-officer-taha-kass-hout-machine-learning-ai/

#1 https://www.massdevice.com/dentsply-sirona-sacks-ceo/

DTW - Hear how Shockwave and  LimFlow are taking the fight to  peripheral vascular diseases

Nearly 700,000 people die from heart disease, that’s one out of every five deaths, a startling number that could be curtailed with better predictive tools. In this episode, we’ll talk with two medical device companies employing new analytical tools to get a clearer picture of heart health. We’ll first connect with Campbell Rogers, MD, executive vice president and chief medical officer of HeartFlow, who will explain how the company’s HeartFlow FFRCT Analysis tool can bring new data to bear. Then, we’ll connect with James Min, MD, co-founder and CEO of Cleerly, a start-up employing artificial intelligence and other tools that he says will help dispel the mystery of this elusive killer.

How Cleerly and HeartFlow are hunting a massive, but still elusive killer – heart disease

In this week’s interview we talk with one of the newer orthopedics players on the block – Enovis, the entity formerly known as Colfax. CEO Matthew L. Trerotola walks us through the decision to move from a diversified industrial player into an orthopedics company and just how the company thinks it can compete against larger, established players in the market. Enovis is weighted heavily in extremities, putting it on a track for fast growth, but sees promising signs it can compete in large joint as well. 

You’ll also hear our latest Fastball Patch from Cellular Vehicles. This episode was sponsored by DeviceTalks Boston.

Thank you for listening to the DeviceTalks Weekly podcast.

Subscribe on any major podcast player.

Enovis bets big on ortho. CEO Matt Trerotola explains why the company has a winning hand

In this episode of IntuitiveTalks, David Robinson, VP of Multiport Design Engineering at Intuitive, delves into the intricacies of the company's multiport system, a flagship product that has been continuously refined since its inception.

Robinson discusses the development of the surgical stapler and the surgical table, two key system components, and highlights the unique challenges faced in designing a robotic surgical stapler and ensuring the surgical table could move in sync with the robotic arms for precise operations.

The episode also explores the evolution of the multiport system and how additions like the stapler, vessel sealer, and table motion capability have significantly enhanced the system's functionality.

Finally, Robinson underscores the importance of critical feedback from surgeons in driving these improvements and shares his excitement about the future of Intuitive Surgical and the impact of their work on improving patient care. Tune into this episode for a fascinating look into the world of robotic-assisted surgery and the ongoing efforts to enhance surgical precision and patient outcomes.

Join us and hundreds of other medtech insiders at DeviceTalks West, October 18-19 in Santa Clara, Ca. Find out more at west.devicetalks.com.

Thank you for listening to the IntuitiveTalks Podcast.

Subscribe to this podcast on every major podcast platform.

Intuitive’s Robinson shares a deeper look into the design challenges of a multi-port surgical system

This special episode of Boston Scientific Talks brings you DeviceTalks Boston’s keynote conversation with Boston Scientific's executive leaders Meghan Scanlon, President of Urology; Jennifer Saunders, Sr. Manager of Medical Affairs; Ben Cutone, Global Franchise Director of Prostate Health; and Kristin LaRocca, Senior Vice President of Sales.

In the conversation, the key figures delve into the innovative strategies and technologies shaping the urology field, highlighting the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System. They explore how Boston Scientific is addressing care disparities in underrepresented communities, pioneering programs like "close the gap" in cardiology, and advancing accessibility and equality. The conversation also highlights the importance of data-driven decision-making, clinical evidence, and humble dialogue with clinicians to commercialize innovative strategies. The panelists discuss the challenges and rewards of disrupting the market, the role of health economics, and the unique contributions of urologists as innovators. They also touch on commercial modeling and the importance of empathy, self-awareness, and courage in bringing new ideas to life. Tune in to discover how Boston Scientific is not only advancing urological care but also the way the leadership team approaches problems and solutions.

Thank you to Clari for sponsoring this episode of Boston Scientific Talks. Go to Clari.com to learn about its unique revenue platform.

Thank you for listening to the Boston Scientific Podcast. Subscribe to this podcast on every major podcast platform.

Boston Scientific executives talk urology innovation, disparities in care, and commercial strategy

In this episode of Boston Scientific Talks, Sandra Nagale, PhD, Director of Digital Health Platforms and Products, breaks down the transformative role of AI within the medical device industry.
Motivated to drive impactful changes, Nagale emphasizes Boston Scientific's unwavering dedication to pioneering breakthrough medical solutions and enhancing patient and physician experiences through AI and emphasizes how products like BeatLogic and LUX-Dx ICM are redefining healthcare by providing actionable, real-time insights.

Navigating the complexities of melding AI with healthcare, Nagale accentuates the necessity for solutions rooted in evidence that genuinely amplifies value. She highlights the urgency to streamline patient experiences, mitigate healthcare worker challenges, and elevate the patient journey. As Boston Scientific spearheads these advancements, Nagale envisions a future where medical devices seamlessly integrate into holistic patient care – from early detection to treatment. Dive into this episode to uncover how Boston Scientific is steering the medtech industry into an AI-augmented future.

Thank you to S3 Connected Health for sponsoring this episode of Boston Scientific Talks. For more information about S3 Connected Health, go to s3connectedhealth.com.

Thank you for listening to the Boston Scientific Podcast.

Subscribe to this podcast on every major podcast platform.

Boston Scientific's Sandra Nagale predicts the future of medtech powered by AI innovations

In this week’s episode we’ll speak with Rocco De Bernardis, Global President of OTTAVA, Johnson & Johnson MedTech. This week, J&J MedTech announced it was filing an IDE to begin clinical trials on its surgical robotics system, Ottava, in 2024. But what does this mean? What does Ottava look like? Why does J&J MedTech think it has what it takes to win over surgeons? And what does the future look like for the company’s surgical robotics platform?

Co-hosts Tom Salemi and Chris Newmarker also chat with Karthik Bolisetty, senior associate at VC firm Gilde Healthcare, about the impact GLP-1 drugs could have on medical device start-ups. How does Gilde see the weight loss drugs impacting its portfolio and future investments?

Finally, Gregg Tobin, CEO of Aptyx, our episode sponsor, talks about how the company’s new name better reflects its capabilities. Go to Aptyx.com for more information.

Thanks for listening to the DeviceTalks Weekly podcast.

Subscribe to the DeviceTalks Podcast Network on any major podcast application.

Hear Why J&J Medtech Is Ready to Move Forward with Ottava; A VC Discusses the Impact of GLP-1 drugs

In the inaugural episode of Ortho Innovation Talks: Zimmer Biomet, Rachel Ellingson, SVP and Chief Strategy Officer at Zimmer Biomet, shares insights into the company's growth strategy, emphasizing that growth can be achieved not only through addition - like innovation and acquisition - but also through subtraction, such as exiting lower growth, non-core businesses. 

In the episode, Ellingson discusses the decision to spin off Zimmer Biomet's spine and dental businesses and the significant undertaking required to create a new public company, which required integrating and then disintegrating business segments, building corporate infrastructure, and establishing a dedicated leadership team for the new entity - a major initiative involving over 500 people and a dedicated separation management office.

Lastly, Ellingson discusses what's next in Zimmer Biomet's growth strategy, citing a balance between internal innovation and M&A and noting that the company plans to launch over 40 new products in the next 36 months, focusing on markets with at least 4% growth. 

Thank you to our season one sponsors, AcuityMD and Millstone Medical for supporting this podcast. To learn more about our episode sponsor, AcuityMD, please visit http://acuitymd.com.

Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

WATCH and LISTEN below, thank you for supporting Ortho Innovation Talks!

S1 Ep 1 - Zimmer Biomet's Rachel Ellingson on driving growth through portfolio shifts and M&A

This episode of DeviceTalks AI offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company.

Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says.

Join us for the next episode of DeviceTalks AI, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic.

Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.
catalyzehealthcare.com
smarttrak.com

Tune in and subscribe to DeviceTalks AI on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

WATCH, LISTEN, and READ: https://www.drugdiscoverytrends.com/when-will-drug-development-have-its-chatgpt-moment-inside-ambitious-ai-initiatives-at-sanofi-and-medable/

Thank you for supporting DeviceTalks AI!

Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials

In this episode of the DeviceTalks Weekly podcast, Kevin Chaplin, CEO of Kardium, a Vancouver-based electrophysiology device company, shares details of the company’s Globe® Pulsed Field Mapping and Ablation System. With $100 million in new capital, the company is poised to open a new front in the pulsed-field ablation battle.

Thank you to Freudenberg Medical for sponsoring this episode. Go to Freudenbergmedical.com for more information.

Thank you for listening to the DeviceTalks Weekly Podcast.

Subscribe now to the DeviceTalks Podcast Network so you don’t miss a future episode.

CEO Chaplin explains how Kardium packed the power of the globe into its PFA cardiac ablation device

In this episode of Ortho Innovation Talks, Jim Lancaster, President of Global Reconstruction at Zimmer Biomet, connects his deep roots in Warsaw, Indiana—known as the orthopedic capital of the world—with his current role in shaping the region's future as a global MedTech hub with his efforts to diversify the region's medtech industry, including the partnership with Plug and Play to attract new innovations in sensor technology and augmented reality, and by driving technical innovations at Zimmer Biomet.

Additionally, Lancaster provides an in-depth look at the development of Persona IQ, the world's first smart knee system, which integrates advanced sensor technology to monitor patient recovery. He also discusses the growing importance of cementless fixation in knee implants, highlighting Zimmer Biomet's focus on enhancing implant longevity and patient outcomes. Lastly, Lancaster discusses Zimmer Biomet's role in surgical robotics, particularly the advancements brought by the Rosa robotics platform, which includes applications for knee, hip, and even shoulder surgeries.

Please join us September 10-12th for DeviceTalks's LIVE Connected Health webinar series. Register at no cost: https://event.on24.com/wcc/r/4613481/E930EFFA706588C378BEAA97824C7CE2/5516160

Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

Thank you for listening to the Ortho Innovation Talks podcast, featuring Zimmer Biomet!

S1 Ep 3 - ZB’s Lancaster talks next-gen knee systems, robotics & building a new regional powerhouse

In this episode of AbbottTalks, Sandra Lesenfants, SVP of Abbott’s structural heart business, discusses the latest advancements in structural heart care, focusing on Abbott's transformative TriClip device for tricuspid regurgitation.

Lesenfants highlights Abbott’s commitment to patient-centered innovation, emphasizing the importance of creating solutions that meet patients’ needs through safe and effective technologies. She also shares Abbott’s approach to expanding access to minimally invasive therapies, particularly in underserved populations worldwide, and the role of physician partnerships in advancing structural heart interventions.

Lastly, Lesenfants underscores the company’s efforts to increase diversity in clinical trials, noting the importance of intentional inclusivity across gender and ethnicity to better serve diverse patient populations.

Thank you to Confluent Medical Technologies for sponsoring this episode of AbbottTalks. For more information on how Confluent Medical works with medical device companies, visit https://confluentmedical.com/.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Lesenfants shares TriClip progress, patient-centered innovation & clinical trial diversity

In this StrykerTalks episode, Andy Pierce, Group President of MedSurg and Neurotechnology at Stryker, shares his insights on the company’s commitment to innovation, growth, and patient-centered care. 

Pierce reflects on his 29-year journey with Stryker, highlighting the high-performance culture shaped by entrepreneurial spirit, growth targets, and strategic acquisitions. He discusses how Stryker’s decentralized structure supports quick, localized decision-making while fostering collaboration across its business units. 

The conversation also explores the company's M&A strategy, focusing on acquisitions that bring de-risked, high-impact technologies that align with Stryker’s long-term goals. Pierce provides an inside look at Stryker's engagement with the soft tissue robotics space, its approach to balancing internal and external innovation, and the proactive steps Stryker takes to address healthcare staffing shortages with technology.

Thank you to Vantedge Medical for sponsoring this episode. To learn more about how Vantedge Medical works with medical device companies, visit www.vantedgemedical.com

Thank you for listening to the StrykerTalks Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Andy Pierce shares how Stryker is “fighting on its front foot” through R&D and aggressive M&A

Where does Iman Jeddi see Intuitive’s da Vinci 5 - and robotics - fit into the future of surgery?

In this episode of IntuitiveTalks, Iman Jeddi, PhD, senior vice president and general manager of the company’s multi port platform, shares a vision for the future of surgery where robotic systems elevate the performance of surgeons and deliver greater care equity.

Jeddi’s career started in biomedical engineering, taking her through several start-ups and ultimately, Abbott. Her lifelong career goal to create technology that improved care for the many led her to join Intuitive Surgical in 2013.

Jeddi has held multiple leadership roles in engineering, operations, and quality. Prior to taking her current post, Jeddi was general manager of the single-port platform, da Vinci SP, so she brings a uniquely comprehensive perspective to the company’s surgical robotic portfolio.

The interview begins and ends with a personal story illustrating her belief in building medical devices and tools that can deliver better care for as many patients as possible.

Thank you to Aptyx for sponsoring this episode of IntuitiveTalks! Please visit www.aptyx.com to learn more about how Aptyx can help you manufacture your competitive edge.

Thank you for listening to the IntuitiveTalks Podcast.

Subscribe to this podcast on every major podcast platform.

Where Intuitive's Iman Jeddi sees da Vinci 5 - and robotics - fitting into the future of surgery

In this episode of AbbottTalks, Kartik Sundareswaran, PhD, divisional VP, global clinical and regulatory affairs, Abbott Heart Failure, discusses Abbott’s pioneering work in heart failure care, focusing on technologies that improve outcomes and empower earlier interventions.

Sundareswaran’s path to MedTech began with a shift from computer engineering to biomedical research, where his early work studying blood flow patterns in children with congenital heart disease sparked a passion for solving cardiovascular challenges. This passion led him to roles at Thoratec, St. Jude Medical, and ultimately Abbott, where he has spent years advancing heart failure care.

The conversation highlights Abbott’s CardioMEMS™ Heart Failure System, a device enabling remote pulmonary artery pressure monitoring to reduce hospitalizations, and the HeartMate 3 LVAD, which provides life-extending support for patients with advanced heart failure. Sundareswaran also discusses the new TEAM-HF clinical trial, which combines CardioMEMS and HeartMate 3 to identify patients earlier and deliver timely, effective interventions.

This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about how Tecan works with medical device companies, visit: https://partnering.tecan.com/

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Sundareswaran envisions TEAM-HF & earlier interventions to redefine heart failure outcomes

In this episode of the DeviceTalks Weekly Podcast, we get an inside look into why Boston Scientific’s AF Solutions division has experienced such a meteoric rise over the past few years. CMO Dr. Brad Sutton lays out the problem facing patients and physicians when treating atrial fibrillation and how acquisitions of pulsed-field ablation tool FARAPULSE is changing the game.

This episode is sponsored by Freudenberg Medical. To discuss a partnership with Freudenberg Medical for your EP catheter portfolio, please visit https://ep.freudenbergmedical.com/.

Chris Newmarker of MassDevice joins Host Tom Salemi in delivering this week’s Newmarker’s Newsmakers - Abbott, Boston Scientific, Intuitive, and Medtronic.

Thank you for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Boston Scientific’s Brad Sutton explains why FARAPULSE may be part of the best story in MedTech

In this episode of the DeviceTalk Weekly podcast, Host Tom Salemi talks with MedTech legend Daniel Hawkins, a serial entrepreneur who has a hand in many industry success stories. He was employee number six at Intuitive before setting out on a path of innovation, developing the technologies around companies like Shockwave Medical.

More recently, Hawkins was CEO of Avail Medsystems, the presumed leader of the pack of companies trying to redefine OR communications, but that company shuttered last year when it couldn’t raise additional capital.

Today, Hawkins is leading Vista.ai, which is selling an AI-enabled package that makes it much easier for MRI technologists to capture meaningful images of the heart. Hawkins sees Vista.ai as improving patient care while also helping imaging centers address the crushing shortfall of experts.

This episode is sponsored by DeviceTalks Boston. Register to attend our April 30-May 1 event of the year at Boston.Devicetalks.com.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss out on a future episode.

Why proven MedTech inventor and CEO Daniel Hawkins sees a huge opportunity in AI-powered MRIs

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi talks with Highridge CEO Rebecca Whitney and Executive Chairman Eric Major about the swirling spinal market. Whitney and Major share what makes the spine industry different from other MedTech sectors and why they believe Highridge is uniquely positioned to grab a large piece of the market.

The episode is sponsored by DeviceTalks Boston. Register to attend at Boston.DeviceTalks.com.

DeviceTalks listeners can find our first interview with the Highridge team here. https://www.devicetalks.com/hear-highridge-medicals-plans-to-scale-the-spine-market-a-preview-of-the-medtechvision-conference/

MassDevice Editor Chris Newmarker returns with the Newmarker’s Newsmakers sharing stories about Stereotaxis, the FDA, Philips, Zimmer Biomet, and Stryker.

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Highridge Medical leaders say the spunout startup is ready to battle for spine market supremacy

In 2024, only months before the world lost Dr. Nick Hopkins, Host John Murray, sat down with Dr. Hopkins to discuss his innovative treatments in stroke care, the necessity of collaboration and partnerships to advance research and clinical care, and the importance of mentorship and training the next generation of neurosurgeons.
 
In this special memorial episode, we hear Dr. Hopkins reflect on “not doing everything by the book, but looking around to ask: is there a better way than what’s in the book?” He shares his philosophy on embracing and learning from mistakes that have fueled advancements in neurovascular methodologies and inspired a culture of openness in the medical community. 
 
A champion of mentorship, Dr. Hopkins has acted as a guiding force for numerous professionals, shaping the future of neurovascular surgery. The episode also delves into the ethical and moral compass that underlies Dr. Hopkins’ work, reaffirming the profound humanity that anchors his approach to both his profession and personal life.
 
To honor the depth of Dr. Hopkins’ legacy, we hear directly from many of his mentees and fellows, including Dr. Adnan Siddiqui, Dr. Ricardo Hanel, Dr. Chuck Kerber, Dr. J. Mocco, Dr. Qureshi, Dr. Raphael Rodriguez, Dr. Demetrius Lopes, and Dr. Ajay Wakhlo on the personal and professional impact he has had on their lives and careers.

Thank you to Zeus for sponsoring this episode of Neuro Innovation Talks. To learn more about how Zeus supports medical device companies, visit: www.zeusinc.com.

Special thanks to Dr. Hopkins’s mentees and fellows who shared their stories and to the following for their support in the development of this podcast: Joanna Colangelo, Mark Dickinson, Whitney Garrett, Tracy Murray, SYK, and Dr. Elad Levy.

Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks to never miss an episode.

Thank you for supporting the Neuro Innovation Talks podcast!

Special Memorial Episode: John Murray and Dr Nick Hopkins Discuss Multidisciplinary Neuro Innovation

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi talks with Dr. Maria Artunduaga, the founder and CEO of Samay, a startup that’s using acoustic energy to get a clearer picture of the lung’s performance. Family tragedy and professional frustration set Dr. Artunduaga on a course that won MedTech Innovator’s Grand Prize. She has the giant check to prove it.

This episode was sponsored by DeviceTalks Boston. You can register at Boston.DeviceTalks.com.

Rachel Robinson, COO of MassMEDIC, joins us on the Newmarker’s Newsmakers. Before we hit the news of the week, Robinson gave a preview of the upcoming MassMEDIC’s Symposium & Gala on March 6.

Go to MassMEDIC.com for more information.

MassDevice Executive Editor Chris Newmaker then delivers news on - Boston Scientific, ResMed, Globus Medical, BD and Baxter. Hilarity ensues.

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

How Samay’s CEO came up with the `sound’ idea for a device to battle COPD, win MedTech Innovator

In this episode of the DeviceTalks Weekly Podcast, Meghan Scanlon, SVP and president of urology at Boston Scientific, updates us on the integration of its powerhouse neurostim acquisition – Axonics. Scanlon also offers great insights on what makes the urology business such a powerful specialty for physicians and medical device executives.

Go here to listen to Scanlon’s first visit with DeviceTalks Weekly. https://www.devicetalks.com/boston-scientific-and-zenflow-are-bringing-critical-new-tools-to-help-urologists-treat-patients/

DeviceTalks Managing Editor Kayleen Brown sits down with Kevin Dempsey, senior director of business development at Tecan, about the opportunities in neuromodulation. Tecan is the sponsor of this episode. To learn more about Tecan visit, https://partnering.tecan.com/

MassDevice Editor Chris Newmarker brings a basket of Newmarker’s Newsmakers including Inspire Medical, Kestra Medical, MGB Layoffs, Medtronic and Johnson & Johnson.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss an episode.

Boston Scientific’s Scanlon shares secrets to good integration, power of compassion for patients

In this episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker sits down with Wayne Paterson, CEO of Anteris Technologies, a unique start-up that’s approaching the complicated and competitive TAVR market.

Chris Newsmaker and Host Tom Salemi also discuss this week’s Newmarker’s Newsmakers including Medtronic, Boston Scientific, Johnson & Johnson MedTech, NeuroPace and the FDA.

This episode was sponsored by DeviceTalks Minnesota. Register to attend the June 11 event at Minnesota.DeviceTalks.com.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

How an artful pivot and IPO is positioning Anteris Technologies to take on the red hot TAVR space

In this episode of the DeviceTalks Weekly Podcast, it’s a DeviceTalks Team Up. Editorial Director Tom Salemi and Managing Editor Kayleen Brown interview Doug Evans, CEO and President of Lungpacer Medical. Evans shares the tragic reason he vowed to start a company that would help wean patients off ventilators. We’ll hear his success story in the podcast, but join us at DeviceTalks Boston to hear the story behind the AeroPace technologies as Evans will be joined by Lungpacer COO Viral Thakkar and Mike Longo, vice president of product development.

Register to attend DeviceTalks Boston at Boston.DeviceTalks.com. If you missed our early bird rate use the code mentioned in the podcast on March 1 and 2.

Before the DeepDive conversation, we’ll have Mass Device Honcho Chris Newmarker’s Newsmakers - Medtronic, Solventum, FDA layoffs, Boston Scientific, and Teleflex.  

Jim Hammerand, managing editor of Medical Design & Outsourcing, opens with an overview of the magazine’s current Min-Vasive issue. You can find all the articles mentioned at medicaldesignandoutsourcing.com.

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Hear Part 1 of Lungpacer Medical’s AeroPace Story; Be part of the conclusion at DeviceTalks Boston

In the kickoff episode of Season 2 of Ortho Innovation Talks, Louie Vogt, Group President of Reconstructive at Enovis, takes us inside the company’s strategic growth in orthopedics. Vogt shares how Enovis has transformed into a major player in the reconstructive space through key acquisitions and bold bets on innovative implant designs.

He discusses the evolution of knee implants, highlighting Enovis’ pioneering work with kinematically driven bearings and the dual pivot knee concept. Vogt also touches on the growing role of robotics and enabling technologies in orthopedic surgery, emphasizing how these advancements are changing the surgeon experience and patient outcomes.

Beyond knees, Vogt explores Enovis’ expansion into foot and ankle reconstruction—a rapidly growing market—and how the company is leveraging M&A and innovation to carve out a competitive edge. As Enovis looks ahead to 2025, Vogt teases major product launches in shoulders, hips, and extremities, signaling another big year for the company.

This conversation comes to you courtesy of our sponsor, Paragon Medical. To learn more about how Paragon Medical can help you bring your device to market faster, visit them at www.paragonmedical.com.

Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

WATCH and LISTEN below, thank you for supporting Ortho Innovation Talks!

Enovis’ Vogt on driving recon growth past $1B w/ M&A, knee breakthroughs and foot & ankle expansion

In this week’s episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker talks with SynCardia CEO Patrick Schnegelsberg and COO Matthew Schuster. Twenty years after FDA approval, SynCardia is the only company with a commercially available total artificial heart, with more than 2,000 implants. Now they're developing what they think will be a game-changer for the technology: a next-gen artificial heart called the Emperor that will be a fully implantable version, without external drivers.

But before the interview Host Tom Salemi gives a quick recap of the MassMedic Symposium and Gala. Then, Chris Newmarker and Senior Editor Danielle Kirsh unpack MassDevice’s new report on surgical robotic companies.

You can download the report for free here. https://www.massdevice.com/gated/massdevices-surgical-robotics-special-report-2025/

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Will SynCardia's Emperor be capable of boldly going where no artificial heart has gone before?

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Todd Langevin, president of BIOTRONIK Neuro, a familiar name in medical devices with a new approach to alleviating pain through spinal cord stimulation. Langevin, who has spent his career in neuro devices, gives his assessment of the field today, explaining how it’s exceeded his early expectations.

Just before that Tom talks with Joe Mullings of The Mullings Group and Surgical Robotics Expert Steve Bell about the state of the surgical robotics industry. The trio will talk about current leaders, emerging powers, and how a shift toward cardiac surgeons could change the playing field completely.

But to start, MassDevice Editor Chris Newmarker joins Tom for the Newmarker’s Newsmakers, the leading stories from the pages of MassDevice. This week’s newsmakers include Tariffs, Medtronic, Surgical Robotics, Stryker, and BCI company Paradromics.

Thank you for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

BIOTRONIK Neuro’s Langevin talks power of connected spinal stim; What’s Next in Surgical Robotics

In this episode of the DeviceTalks Weekly podcast, Host Tom Salemi interviews Alan Lotvin, MD, the CEO and co-founder of Sequel Med Tech, a small company promoting another BIG idea from prolific inventor Dean Kamen. Lotvin, who was formerly a senior executive at CVS/Caremark and PBMs, explains how Twiist, the automated insulin delivery system, could be a game-changer for people with diabetes.

Before the interview, we’ll hear from Ivan Tornos, the CEO and president of Zimmer Biomet. Tornos, who is the opening keynote interview guest at DeviceTalks Boston on April 30 at the Boston Convention & Exhibition Center talks with Salemi and Joe Mullings about the the changes at Zimmer Biomet and in orthopedics.

Register to see Tornos live at Boston.DeviceTalks.com. Use the code mentioned in the podcast to save 25%.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Lotvin on why this Sequel AID is better than the original; ZB’s Tornos highlights new tech, ASCs

Gary Guthart, the longtime CEO of Intuitive Surgical, tells MassDevice.com Executive Editor Brad Perriello why he's so confident about staying on top of the robot-assisted surgery heap, the company's five buckets for in-house R&D; and what he looks for in potential business partners.

Intuitive Surgical CEO Gary Guthart plans to stay on top

Nadim Yared, CEO of CVRx

This week, CVRX reported positive six-month trial results for its Barostim Neo, an FDA-approved treatment for heart failure.

The results follow years of close work between the agency and CVRx, one of the more ambitious startups in medtech. CVRx is targeting a huge clinical need with novel neuromodulation technology.

In this week’s DeviceTalks Weekly podcast, CEO Nadim Yared walks us through the negotiations the company went through with the FDA to get to this point.

Yared, the prior chairman of the industry group AdvaMed, also shares the story of his career, which started early on when he secured a job at GE even before graduating college.

In this talk, Yared speaks to several issues including:

The power of confidence and the dangers of overconfidence when building a career.
-How he decided to take the job at CVRx (and why he didn’t initially want to talk about the job with a recruiter.)
-What CVRx learned from other successes and failures in renal denervation.
-Why the company is betting big on heart failure, but doesn't have a Chief Medical Officer.
-Whether or not his role as chairman at AdvaMed impacted his work at CVRx.
-Can medtechs generate good returns after raising hundreds of millions in capital?

This conversation took place prior to the emergence of COVID-19, so DTW host Tom Salemi visited again with Yared more recently. We’ll play that interview in next week’s episode of DeviceTalks Weekly.

If you’re looking for more medtech discussions, register now for DeviceTalks Weekly at devicetalks.com.

Subscribe to he podcast. Don’t miss an episode!

CVRx CEO Nadim Yared on his path from engineer to CEO to industry leader.

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

DeviceTalks

Popular tracks